AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/24/2026

1. SPY
2. KBH
3. PATH
4. USO
5. AZO
6. QQQ
7. META
8. ORCL
9. RCL
10. ONON

Go back to AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
AbbVie (NYSE: ABBV) Delayed: 265.08 -0.13 (0.05%)
Previous Close $265.21    52 Week High $68.12 
Open $266.00    52 Week Low $50.71 
Day High $269.39    P/E 57.50 
Day Low $263.59    EPS $4.61 
Volume 3,469,241       

ENANTA PHARM (NASDAQ: ENTA) Delayed: 11.95 -0.47 (3.78%)
Previous Close $12.42    52 Week High $34.49 
Open $12.33    52 Week Low $20.39 
Day High $12.33    P/E N/A 
Day Low $11.87    EPS $-3.18 
Volume 206,349